CellCentric Raises $26M to Advance Prostate Cancer Therapy Candidate CCS1477

CellCentric Raises $26M to Advance Prostate Cancer Therapy Candidate CCS1477
Biotechnology company CellCentric recently raised $26 million in private funding to advance clinical testing of its first-in-class therapy candidate CCS1477 as a treatment for prostate cancer. CCS1477 addresses the growing population of patients whose tumors have inherent or acquired resistance to second-generation androgen deprivation therapies through a different approach than current therapies that tackle resistance. The

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *